-
PDF
- Split View
-
Views
-
Cite
Cite
Y Sotomi, S Tamaki, S Hikoso, D Nakatani, K Okada, T Dohi, M Seo, Y Masamichi, T Hayashi, A Nakagawa, Y Nakagawa, T Ohtani, Y Yasumura, T Yamada, Y Sakata, Pathophysiological insights into machine-learning-based subphenotypes of acute heart failure with preserved ejection fraction: a biomarker analysis of PURSUIT-HFpEF registry, European Heart Journal, Volume 44, Issue Supplement_2, November 2023, ehad655.742, https://doi.org/10.1093/eurheartj/ehad655.742
- Share Icon Share
Abstract
Our understanding of heart failure with preserved ejection fraction (HFpEF) has evolved from mere left ventricular diastolic dysfunction to a multiorgan disease.
This study aimed to investigate the heterogeneous pathophysiology of the several phenotypes of HFpEF with multiple biomarker data.
This study is a post-hoc analysis of the PURSUIT-HFpEF study (N=1,231), an ongoing, prospective, multi-referral center, observational study of acute decompensated HFpEF [UMIN000021831]. In this registry, there is a pre-defined sub-cohort in which we perform multi-biomarker tests (N=212). We applied the machine-learning-based clustering model that we have previously established to the sub-cohort and classified them into 4 phenotypes: phenotype 1 labeled as "rhythm trouble" (n=69), phenotype 2 "ventricular-arterial uncoupling" (n=49), phenotype 3 "low output and systemic congestion" (n=41), and phenotype 4 "systemic failure" (n=53). Characteristics of biomarker tests in each phenotype were evaluated.
The phenotype 2 characterized by hypertension and cardiac hypertrophy showed the highest value of N-terminal pro-brain natriuretic peptide (NT-proBNP), IL-16, high-sensitive C-reactive protein (CRP), tumor necrosis factor (TNF)-α, growth differentiation factor (GDF)-15, troponin T, and cystatin C, whereas the phenotype 1 presented the lowest value of these markers. The phenotype 3 showed the second highest value of GDF-15 and cystatin C. The phenotype 4 presented a low NT-proBNP value and a relatively high GDF-15.
Author notes
Funding Acknowledgements: Type of funding sources: Private company. Main funding source(s): Roche Diagnostics K.K. and Fuji Film Toyama Chemical Co. Ltd.
- heart failure, acute
- phenotype
- hypertension
- tumor necrosis factors
- cardiomegaly
- patient referral
- inflammation
- heterogeneity
- biological markers
- heart ventricle
- interleukin-16
- troponin t
- c-reactive protein
- ejection fraction
- left ventricular diastolic dysfunction
- cystatin c measurement
- nt-probnp
- growth differentiation factor 15
- heart failure with preserved ejection fraction
- rhythm
- machine learning